数据显示，工银瑞信基金旗下1只基金位居三生国健十大流通股东。工银前沿医疗股票A（001717）二 季度新进十大流通股东，持有股数319.9万股，占流通股的比例为0.52%。根据测算，今日浮盈赚取约 815.76万元。 工银前沿医疗股票A（001717）成立日期2016年2月3日，最新规模93.3亿。今年以来收益22.77%，同类 排名2183/4220；近一年收益15.15%，同类排名2740/3857；成立以来收益223%。 工银前沿医疗股票A（001717）基金经理为赵蓓。 10月15日，三生国健涨5.08%，截至发稿，报52.70元/股，成交8896.70万元，换手率0.28%，总市值 325.05亿元。 资料显示，三生国健药业(上海)股份有限公司位于中国(上海)自由贸易试验区李冰路399号，成立日期 2002年1月25日，上市日期2020年7月22日，公司主营业务涉及抗体药物的研发、生产及销售业务。主营 业务收入构成为：销售商品75.24%，提供委托加工服务15.37%，授权许可7.94%，租赁服务1.44%。 从三生国健十大流通股东角度 截至发稿，赵蓓累计任职时间10年335天，现任基金资产总规模1 ...

Group 1 - Baiyang Pharmaceutical has experienced a decline for four consecutive trading days, with a cumulative drop of -3.93% [1] - The company, established in 2005, focuses on the development, manufacturing, and commercialization of medical innovations, aiming to optimize healthcare through technological advancements [1] - ICBC Credit Suisse Asset Management has two funds among the top ten shareholders of Baiyang Pharmaceutical, with one fund reducing its holdings and the other entering the position in the second quarter of this year [1] Group 2 - ICBC Credit Suisse Fund's "ICBC Frontier Medical Stock A" has a year-to-date return of 33.52%, ranking 190 out of 976 in its category, while "ICBC Healthcare Stock" has a return of 32.51%, ranking 206 out of 976 [2] - The fund managers for these funds are Zhao Bei and Ding Yang, with Zhao having over ten years of experience in the industry and currently managing multiple funds [5][6] - Ding Yang, who joined ICBC Credit Suisse in December 2017, has been managing the healthcare industry stock fund since May 2023 [7]

Group 1 - The core point of the article highlights the performance and holdings of the ICBC Frontier Medical Stock A fund, which has a recent net value of 3.4760 yuan and a decline of 0.52% [1] - The fund's one-month return is 1.67%, ranking 964 out of 1023 in its category; the six-month return is 30.63%, ranking 115 out of 984; and the year-to-date return is 32.12%, ranking 222 out of 974 [1] - The top ten holdings of the fund account for a total of 59.44%, with significant positions in companies such as Heng Rui Pharmaceutical (9.51%), Kelun Pharmaceutical (9.16%), and others [1] Group 2 - The ICBC Frontier Medical Stock A fund was established on February 3, 2016, and as of June 30, 2025, it has a total scale of 9.33 billion yuan [1] - The fund manager, Zhao Bei, has extensive experience in the healthcare sector, having held various positions since joining ICBC Credit Suisse in 2010 [2]

Group 1 - The core point of the article highlights the performance and holdings of the ICBC Frontier Medical Stock A fund, which has a recent net value of 3.3960 yuan, reflecting a decline of 2.19% [1] - The fund has shown a one-month return of 10.22%, a six-month return of 29.67%, and a year-to-date return of 29.08%, with respective rankings of 252 out of 1022, 86 out of 985, and 130 out of 975 in its category [1] - The top ten holdings of the fund account for a total of 59.44%, with significant positions in companies such as Heng Rui Pharmaceutical (9.51%), Kelun Pharmaceutical (9.16%), and Xinlitai (6.70%) [1] Group 2 - The ICBC Frontier Medical Stock A fund was established on February 3, 2016, and as of June 30, 2025, it has a total scale of 9.33 billion yuan, managed by fund manager Zhao Bei [1] - Zhao Bei holds a master's degree and has extensive experience in the investment management field, having served in various roles since joining ICBC Credit Suisse in 2010 [2]

Group 1 - The core viewpoint of the news is the performance and holdings of the ICBC Frontier Medical Stock A fund, which has shown significant growth in recent months and has a diversified portfolio in the healthcare sector [1][3] - As of July 28, 2025, the latest net value of ICBC Frontier Medical Stock A is 3.4240 yuan, reflecting a growth of 3.04%. The fund's one-month return is 13.45%, six-month return is 32.00%, and year-to-date return is 30.14% [1] - The fund's top ten stock holdings account for a total of 59.44%, with significant investments in companies such as Heng Rui Pharmaceutical (9.51%), Kelun Pharmaceutical (9.16%), and others [1] Group 2 - The ICBC Frontier Medical Stock A fund was established on February 3, 2016, and as of June 30, 2025, it has a total scale of 9.33 billion yuan. The fund manager is Zhao Bei [1] - Zhao Bei has extensive experience in the healthcare sector, having served as the fund manager for various healthcare-related funds since 2014 and currently holds multiple managerial positions within ICBC Credit Suisse Asset Management [2]

Group 1 - The core point of the article highlights the performance and holdings of the ICBC Frontier Medical Stock A fund, which has a recent net value of 3.3810 yuan, reflecting a decline of 1.11% [1] - The fund has achieved a return of 12.70% over the past month, ranking 117 out of 717 in its category; a return of 29.84% over the past six months, ranking 54 out of 704; and a year-to-date return of 28.51%, ranking 62 out of 702 [1] - The top ten holdings of the fund account for a total of 59.44%, with significant positions in companies such as Heng Rui Pharmaceutical (9.51%), Kelun Pharmaceutical (9.16%), and Xin Li Tai (6.70%) [1] Group 2 - The ICBC Frontier Medical Stock A fund was established on February 3, 2016, and as of June 30, 2025, it has a total scale of 9.33 billion yuan, managed by fund manager Zhao Bei [1] - Zhao Bei holds a master's degree and has extensive experience in the investment management field, having worked in various roles since joining ICBC Credit Suisse in 2010 [2]

Group 1 - The core viewpoint of the article highlights the performance and outlook of the AI Fund ICBC Frontier Medical Stock A, which reported a profit of 780 million yuan in Q2 2025, with a net value growth rate of 9% [2] - As of July 18, 2025, the fund's unit net value was 3.419 yuan, and the fund manager, Zhao Bei, oversees five funds that have all achieved positive returns over the past year [2] - The fund's management indicates a stabilization trend in consumer medical demand since the first half of 2025, with ongoing observations needed for sustained recovery [2] Group 2 - The fund's recent performance metrics show a three-month net value growth rate of 21.85%, a six-month growth rate of 33.03%, and a one-year growth rate of 29.61%, ranking it 36/54, 35/54, and 37/53 among comparable funds respectively [3] - The fund's three-year Sharpe ratio is -0.0663, placing it 24/46 among comparable funds, while the maximum drawdown over the same period is 34.88%, ranking 33/46 [8][10] - As of Q2 2025, the fund's total assets amounted to 9.33 billion yuan, with the top ten holdings including major pharmaceutical companies such as Heng Rui Medicine and BeiGene [15][18]

Group 1 - The core viewpoint of the news is the performance and holdings of the ICBC Frontier Medical Stock A fund, which has shown a recent net value increase of 1.05% and notable returns over various time frames [1] - The fund's recent one-month return is -1.03%, ranking 791 out of 826 in its category, while its six-month return is 23.38%, ranking 99 out of 804, and year-to-date return is 20.94%, ranking 101 out of 801 [1] - The top ten stock holdings of the fund account for a total of 59.05%, with significant positions in companies such as Heng Rui Pharmaceutical (10.11%), Kelun Pharmaceutical (8.01%), and WuXi AppTec (7.72%) [1] Group 2 - The ICBC Frontier Medical Stock A fund was established on February 3, 2016, and as of March 31, 2025, it has a total scale of 9.081 billion yuan [1] - The fund manager, Zhao Bei, has extensive experience in the healthcare sector, having held various positions since joining ICBC Credit Suisse Asset Management in 2010 [2]

Group 1 - The core point of the article highlights the performance and holdings of the Industrial Bank's Frontier Medical Stock A fund, which has a recent net value of 3.0810 yuan, down by 2.50% [1] - The fund's performance over the past month shows a return of -1.41%, ranking 584 out of 646 in its category; over the past six months, it has achieved a return of 21.49%, ranking 76 out of 625; and since the beginning of the year, it has returned 17.10%, ranking 85 out of 623 [1] - The top ten holdings of the fund account for a total of 59.05%, with significant positions in companies such as Heng Rui Pharmaceutical (10.11%), Kelun Pharmaceutical (8.01%), and WuXi AppTec (7.72%) [1] Group 2 - The Industrial Bank's Frontier Medical Stock A fund was established on February 3, 2016, and as of March 31, 2025, it has a total scale of 9.081 billion yuan, managed by Zhao Bei [1] - Zhao Bei holds a master's degree and has extensive experience in the investment management field, having served in various roles since joining Industrial Bank in 2010, including as the head of the healthcare research team [2]

Group 1 - The core point of the news is the performance and holdings of the Industrial Bank's Frontier Medical Stock A fund, which has shown a recent decline in net value but positive returns over various time frames [1] - As of June 20, 2025, the latest net value of the fund is 3.0000 yuan, reflecting a decrease of 0.60% [1] - The fund's one-month return is 1.83%, ranking 193 out of 1019 in its category; the six-month return is 11.15%, ranking 122 out of 986; and the year-to-date return is 14.03%, ranking 107 out of 990 [1] Group 2 - The top ten holdings of the fund account for a total of 59.05%, with significant positions in companies such as Heng Rui Pharmaceutical (10.11%), Kelun Pharmaceutical (8.01%), and WuXi AppTec (7.72%) [1] - The fund was established on February 3, 2016, and as of March 31, 2025, it has a total scale of 9.081 billion yuan [1] - The fund manager is Zhao Bei, who has extensive experience in the healthcare sector and has been managing this fund since its inception [2]